@article{e786958353564b8c876c5b20da8a451e,
title = "How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment — a bidding game experiment",
abstract = "Background: To estimate the perceived value of additional testing with amyloid-PET in Euros in healthy participants acting as analogue patients with mild cognitive impairment (MCI). Methods: One thousand four hundred thirty-one healthy participants acting as analogue MCI patients (mean age 65 ± 8, 929 (75%) female) were recruited via the Dutch Brain Research Registry. Participants were asked to identify with a presented case (video vignette) of an MCI patient and asked whether they would prefer additional diagnostic testing with amyloid PET in this situation. If yes, respondents were asked how much they would be willing to pay for additional diagnostic testing. Monetary value was elicited via a bidding game in which participants were randomized over three conditions: (A) additional testing results in better patient management, (B) Same as condition A and a delay in institutionalization of 3 months, and (C) same as A and a delay in institutionalization of 6 months. Participants who were not willing to take a test were compared with participants who were willing to take a test using logit models. The highest monetary value per condition was analyzed using random-parameter mixed models. Results: The vast majority of participants acting as analogue MCI patients (87% (n = 1238)) preferred additional testing with amyloid PET. Participants who were not interested were more often female (OR = 1.61 95% CI [1.09–2.40]) and expressed fewer worries to get AD (OR = 0.64 [0.47–0.87]). The median “a priori” (i.e., before randomization) monetary value of additional diagnostic testing was €1500 (IQR 500–1500). If an additional amyloid PET resulted in better patient management (not further specified; condition A), participants were willing to pay a median price of €2000 (IQR = 1000–3500). Participants were willing to pay significantly more than condition A (better patient management) if amyloid-PET testing additionally resulted in a delay in institutionalization of 3 months (€530 [255–805] on top of €2000, condition B) or 6 months (€596 [187–1005] on top of €2000, condition C). Conclusions: Members of the general population acting as MCI patients are willing to pay a substantial amount of money for amyloid-PET and this increases when diagnostic testing leads to better patient management and the prospect to live longer at home.",
keywords = "Aged, Alzheimer Disease/diagnosis, Alzheimer{\textquoteright}s disease, Amyloid, Amyloid beta-Peptides, Amyloid-PET, Amyloidogenic Proteins, Bidding game, Cognitive Dysfunction/diagnostic imaging, Diagnostic Techniques and Procedures, Female, Healthy Volunteers, Humans, Male, Middle Aged, Positron-Emission Tomography/methods, Sensitivity and Specificity",
author = "{van Maurik}, {I. S.} and Bakker, {E. D.} and {van Unnik}, {A. A. J. M.} and Broulikova, {H. M.} and Zwan, {M. D.} and J. Berkhof and Bouwman, {F. H.} and Bosmans, {J. E.} and {van der Flier}, {W. M.} and {van de Giessen}, E.",
note = "Funding Information: Research programs of Wiesje van der Flier have been funded by ZonMW, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health ~ Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis-NL, Life-MI, AVID, Roche BV, Fujifilm, Eisai, Combinostics. WF holds the Pasman chair. WF is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health ~ Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). WF has performed contract research for Biogen MA Inc, and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, NovoNordisk, WebMD Neurology (Medscape), Springer Healthcare. WF is consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. WF participated in advisory boards of Biogen MA Inc and Roche. All funding is paid to her institution. WF was associate editor of Alzheimer, Research & Therapy in 2020/2021. WF is associate editor at Brain. Funding Information: Research of Alzheimer center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting Steun Alzheimercentrum Amsterdam. The clinical database structure was developed with funding from Stichting Dioraphte. WMvdF holds the Pasman chair. WMvdF and ISvM are recipients of the EU Joint Programme Neurodegenerative Disease Research project ADDITION (ZonMW, grant no. 733051083) and the collaboration project ABIDE-clinical utility, which is co-funded by the PPP Allowance made available by health-Holland, Top Sector Life Sciences & Health, to stimulate public–private partnerships and Life Molecular Imaging GmbH (grant no.: LSHM18075). WMvdF is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007), Alzheimer Nederland and Health ~ Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners contribute to ABOARD. ABOARD also receives financial support from Gieskes-Strijbisfonds and Edwin Bouw Fonds. The Dutch Brain Research Registry (Hersenonderzoek.nl) is supported by ZonMw‐Memorabel (project no 73305095003; a project in the context of the Dutch Deltaplan Dementie), Amsterdam Neuroscience, Alzheimer Nederland, and Hersenstichting (Dutch Brain Foundation). Publisher Copyright: {\textcopyright} 2023, The Author(s).",
year = "2023",
month = dec,
day = "1",
doi = "https://doi.org/10.1186/s13195-023-01346-y",
language = "English",
volume = "15",
pages = "208",
journal = "Alzheimer's Research and Therapy",
issn = "1758-9193",
publisher = "BioMed Central",
number = "1",
}